DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[14] |
Thioguanine |
DM7NKEV
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Thioguanine. |
Acute myeloid leukaemia [2A60]
|
[12] |
Uracil mustard |
DMHL7OB
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Uracil mustard. |
Acute myeloid leukaemia [2A60]
|
[12] |
Midostaurin |
DMI6E0R
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[12] |
Idarubicin |
DMM0XGL
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[12] |
Daunorubicin |
DMQUSBT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[12] |
Oliceridine |
DM6MDCF
|
Moderate |
Altered metabolism of Infliximab due to Oliceridine alters the formation of CYP450 enzymes. |
Acute pain [MG31]
|
[15] |
Siltuximab |
DMGEATB
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Siltuximab. |
Anemia [3A00-3A9Z]
|
[12] |
Nifedipine |
DMSVOZT
|
Moderate |
Altered metabolism of Infliximab due to Nifedipine alters the formation of CYP450 enzymes. |
Angina pectoris [BA40]
|
[15] |
Bedaquiline |
DM3906J
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[16] |
Alprazolam |
DMC7XDN
|
Moderate |
Altered metabolism of Infliximab due to Alprazolam alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[15] |
Methylphenobarbital |
DMDSWAG
|
Moderate |
Altered metabolism of Infliximab due to Methylphenobarbital alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[17] |
Clobazam - Lundbeck |
DMW1OQ0
|
Moderate |
Altered metabolism of Infliximab due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[15] |
Budesonide |
DMJIBAW
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Budesonide. |
Asthma [CA23]
|
[12] |
Aminophylline |
DML2NIB
|
Moderate |
Altered metabolism of Infliximab due to Aminophylline alters the formation of CYP450 enzymes. |
Asthma [CA23]
|
[15] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Infliximab and Roflumilast. |
Asthma [CA23]
|
[15] |
Dupilumab |
DMOAD2Y
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Dupilumab. |
Atopic eczema [EA80]
|
[12] |
Linezolid |
DMGFPU2
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[12] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Infliximab and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[18] |
Temozolomide |
DMKECZD
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Temozolomide. |
Brain cancer [2A00]
|
[12] |
Lomustine |
DMMWSUL
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Lomustine. |
Brain cancer [2A00]
|
[12] |
Eribulin |
DM1DX4Q
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[12] |
Talazoparib |
DM1KS78
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[12] |
Ixabepilone |
DM2OZ3G
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ixabepilone. |
Breast cancer [2C60-2C6Y]
|
[12] |
LY2835219 |
DM93VBZ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[12] |
Pralatrexate |
DMAO80I
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[12] |
Palbociclib |
DMD7L94
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Palbociclib. |
Breast cancer [2C60-2C6Y]
|
[12] |
Mitomycin |
DMH0ZJE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mitomycin. |
Breast cancer [2C60-2C6Y]
|
[12] |
Thiotepa |
DMIZKOP
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Thiotepa. |
Breast cancer [2C60-2C6Y]
|
[12] |
Cabazitaxel |
DMPAZHC
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Cabazitaxel. |
Breast cancer [2C60-2C6Y]
|
[12] |
Bosutinib |
DMTI8YE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[12] |
Trastuzumab |
DMZQOUX
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Trastuzumab. |
Breast cancer [2C60-2C6Y]
|
[12] |
Atorvastatin |
DMF28YC
|
Moderate |
Altered metabolism of Infliximab due to Atorvastatin alters the formation of CYP450 enzymes. |
Cardiovascular disease [BA00-BE2Z]
|
[15] |
Corticotropin |
DMP9TWZ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Corticotropin. |
Chronic kidney disease [GB61]
|
[12] |
Irinotecan |
DMP6SC2
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Irinotecan. |
Colorectal cancer [2B91]
|
[12] |
Oxaliplatin |
DMQNWRD
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Oxaliplatin. |
Colorectal cancer [2B91]
|
[12] |
Aflibercept |
DMT3D5I
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Aflibercept. |
Colorectal cancer [2B91]
|
[12] |
Capecitabine |
DMTS85L
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Capecitabine. |
Colorectal cancer [2B91]
|
[12] |
Drospirenone |
DM1A9W3
|
Moderate |
Altered metabolism of Infliximab due to Drospirenone alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[15] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Altered metabolism of Infliximab due to Levonorgestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[15] |
Desogestrel |
DM27U4Y
|
Moderate |
Altered metabolism of Infliximab due to Desogestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[17] |
Norgestimate |
DMYP4XC
|
Moderate |
Altered metabolism of Infliximab due to Norgestimate alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[17] |
Lidocaine |
DML4ZOT
|
Moderate |
Altered metabolism of Infliximab due to Lidocaine alters the formation of CYP450 enzymes. |
Corneal disease [9A76-9A78]
|
[15] |
Nimodipine |
DMQ0RKZ
|
Moderate |
Altered metabolism of Infliximab due to Nimodipine alters the formation of CYP450 enzymes. |
Coronary vasospastic disease [BA85]
|
[15] |
Oxtriphylline |
DMLHSE3
|
Moderate |
Altered metabolism of Infliximab due to Oxtriphylline alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[15] |
Methadone |
DMTW6IU
|
Moderate |
Altered metabolism of Infliximab due to Methadone alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[15] |
Mycophenolic acid |
DMRBMAU
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mycophenolic acid. |
Crohn disease [DD70]
|
[12] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Altered metabolism of Infliximab due to Rivaroxaban alters the formation of CYP450 enzymes. |
Deep vein thrombosis [BD71]
|
[15] |
Polatuzumab vedotin |
DMF6Y0L
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[12] |
Lisocabtagene maraleucel |
DMP45ME
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Lisocabtagene maraleucel. |
Diffuse large B-cell lymphoma [2A81]
|
[12] |
PMID28870136-Compound-48 |
DMPIM9L
|
Moderate |
Altered metabolism of Infliximab due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. |
Discovery agent [N.A.]
|
[15] |
Oestradiol valerate and dienogest |
DMZK0FQ
|
Moderate |
Altered metabolism of Infliximab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. |
Endometriosis [GA10]
|
[17] |
Diazepam |
DM08E9O
|
Moderate |
Altered metabolism of Infliximab due to Diazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Primidone |
DM0WX6I
|
Moderate |
Altered metabolism of Infliximab due to Primidone alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Mephenytoin |
DM5UGDK
|
Moderate |
Altered metabolism of Infliximab due to Mephenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Ethosuximide |
DMDZ9LT
|
Moderate |
Altered metabolism of Infliximab due to Ethosuximide alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Phenytoin |
DMNOKBV
|
Moderate |
Altered metabolism of Infliximab due to Phenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Fosphenytoin |
DMOX3LB
|
Moderate |
Altered metabolism of Infliximab due to Fosphenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Clonazepam |
DMTO13J
|
Moderate |
Altered metabolism of Infliximab due to Clonazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Phenobarbital |
DMXZOCG
|
Moderate |
Altered metabolism of Infliximab due to Phenobarbital alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Carbamazepine |
DMZOLBI
|
Moderate |
Altered metabolism of Infliximab due to Carbamazepine alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[15] |
Nicardipine |
DMCDYW7
|
Moderate |
Altered metabolism of Infliximab due to Nicardipine alters the formation of CYP450 enzymes. |
Essential hypertension [BA00]
|
[15] |
Bay 80-6946 |
DMLOS5R
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Bay 80-6946. |
Follicular lymphoma [2A80]
|
[12] |
Avapritinib |
DMK2GZX
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[12] |
177Lu-DOTATATE |
DMT8GVU
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[12] |
Bleomycin |
DMNER5S
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Bleomycin. |
Hodgkin lymphoma [2B30]
|
[12] |
Brentuximab vedotin |
DMWLC57
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[12] |
Zidovudine |
DM4KI7O
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Zidovudine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[12] |
Efavirenz |
DMC0GSJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[19] |
Zalcitabine |
DMH7MUV
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Infliximab and Zalcitabine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[20] |
Simvastatin |
DM30SGU
|
Moderate |
Altered metabolism of Infliximab due to Simvastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[15] |
Lovastatin |
DM9OZWQ
|
Moderate |
Altered metabolism of Infliximab due to Lovastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[15] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Infliximab and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[21] |
BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Infliximab and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[22] |
Nisoldipine |
DM7ISKJ
|
Moderate |
Altered metabolism of Infliximab due to Nisoldipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[15] |
Levamlodipine |
DM92S6N
|
Moderate |
Altered metabolism of Infliximab due to Levamlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[15] |
Isradipine |
DMA5XGH
|
Moderate |
Altered metabolism of Infliximab due to Isradipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[15] |
Amlodipine |
DMBDAZV
|
Moderate |
Altered metabolism of Infliximab due to Amlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[15] |
Felodipine |
DMOSW35
|
Moderate |
Altered metabolism of Infliximab due to Felodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[15] |
Fludrocortisone |
DMUDIR8
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[12] |
Triazolam |
DMETYK5
|
Moderate |
Altered metabolism of Infliximab due to Triazolam alters the formation of CYP450 enzymes. |
Insomnia [7A00-7A0Z]
|
[15] |
Olaratumab |
DMNYOIX
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Olaratumab. |
Kaposi sarcoma [2B57]
|
[12] |
Methotrexate |
DM2TEOL
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Methotrexate. |
Leukaemia [2A60-2B33]
|
[12] |
Nelarabine |
DMB6VEG
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Nelarabine. |
Leukaemia [2A60-2B33]
|
[12] |
DTI-015 |
DMXZRW0
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and DTI-015. |
Liver cancer [2C12]
|
[12] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Infliximab and Denosumab. |
Low bone mass disorder [FB83]
|
[23] |
Brigatinib |
DM7W94S
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Brigatinib. |
Lung cancer [2C25]
|
[12] |
Lurbinectedin |
DMEFRTZ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Lurbinectedin. |
Lung cancer [2C25]
|
[12] |
Osimertinib |
DMRJLAT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Osimertinib. |
Lung cancer [2C25]
|
[12] |
Belimumab |
DM3OBQF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Belimumab. |
Lupus erythematosus [4A40]
|
[12] |
Primaquine |
DMWQ16I
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Primaquine. |
Malaria [1F40-1F45]
|
[12] |
Inotuzumab ozogamicin |
DMAC130
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[12] |
Rituximab |
DM1YVZT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Rituximab. |
Malignant haematopoietic neoplasm [2B33]
|
[12] |
Tositumomab |
DMMYZ3D
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Tositumomab. |
Malignant haematopoietic neoplasm [2B33]
|
[12] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[24] |
Fludarabine |
DMVRLT7
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Fludarabine. |
Malignant haematopoietic neoplasm [2B33]
|
[12] |
Pentostatin |
DM0HXDS
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Pentostatin. |
Mature B-cell leukaemia [2A82]
|
[12] |
Ofatumumab |
DM295PR
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ofatumumab. |
Mature B-cell leukaemia [2A82]
|
[12] |
Obinutuzumab |
DM3BVAE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Obinutuzumab. |
Mature B-cell leukaemia [2A82]
|
[12] |
Cladribine |
DM3JDRP
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Cladribine. |
Mature B-cell leukaemia [2A82]
|
[15] |
Idelalisib |
DM602WT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[12] |
Chlorambucil |
DMRKE63
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Chlorambucil. |
Mature B-cell leukaemia [2A82]
|
[12] |
IPI-145 |
DMWA24P
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and IPI-145. |
Mature B-cell leukaemia [2A82]
|
[12] |
Alemtuzumab |
DMZL3IV
|
Moderate |
Additive immunosuppressive effects by the combination of Infliximab and Alemtuzumab. |
Mature B-cell leukaemia [2A82]
|
[25] |
Acalabrutinib |
DM7GCVW
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[12] |
Clofarabine |
DMCVJ86
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[12] |
Blinatumomab |
DMGECIJ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[12] |
Ibrutinib |
DMHZCPO
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[12] |
Vincristine |
DMINOX3
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Vincristine. |
Mature B-cell lymphoma [2A85]
|
[12] |
Teniposide |
DMLW57T
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Teniposide. |
Mature B-cell lymphoma [2A85]
|
[12] |
Tisagenlecleucel |
DMM9BJD
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Tisagenlecleucel. |
Mature B-cell lymphoma [2A85]
|
[12] |
Mercaptopurine |
DMTM2IK
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[12] |
Ponatinib |
DMYGJQO
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[12] |
Cytarabine |
DMZD5QR
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[12] |
Mechlorethamine |
DM0CVXA
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mechlorethamine. |
Mature T-cell lymphoma [2A90]
|
[12] |
Dacarbazine |
DMNPZL4
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Dacarbazine. |
Melanoma [2C30]
|
[12] |
Ethinyl estradiol |
DMODJ40
|
Moderate |
Altered metabolism of Infliximab due to Ethinyl estradiol alters the formation of CYP450 enzymes. |
Menopausal disorder [GA30]
|
[17] |
Midazolam |
DMXOELT
|
Moderate |
Altered metabolism of Infliximab due to Midazolam alters the formation of CYP450 enzymes. |
Mood/affect symptom [MB24]
|
[15] |
Carfilzomib |
DM48K0X
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Carfilzomib. |
Multiple myeloma [2A83]
|
[12] |
Panobinostat |
DM58WKG
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Panobinostat. |
Multiple myeloma [2A83]
|
[12] |
Thalidomide |
DM70BU5
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Thalidomide. |
Multiple myeloma [2A83]
|
[12] |
Selinexor |
DMBD4K3
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Selinexor. |
Multiple myeloma [2A83]
|
[12] |
Belantamab mafodotin |
DMBT3AI
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Belantamab mafodotin. |
Multiple myeloma [2A83]
|
[12] |
Elotuzumab |
DMEYHG9
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Elotuzumab. |
Multiple myeloma [2A83]
|
[12] |
Daratumumab |
DMKCIUZ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Daratumumab. |
Multiple myeloma [2A83]
|
[12] |
Bortezomib |
DMNO38U
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Bortezomib. |
Multiple myeloma [2A83]
|
[12] |
Melphalan |
DMOLNHF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Melphalan. |
Multiple myeloma [2A83]
|
[12] |
Tecfidera |
DM2OVDT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Tecfidera. |
Multiple sclerosis [8A40]
|
[12] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Fingolimod. |
Multiple sclerosis [8A40]
|
[26] |
Interferon beta-1b |
DMCN61Z
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Interferon beta-1b. |
Multiple sclerosis [8A40]
|
[27] |
Ocrelizumab |
DMEZ2KH
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[12] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ozanimod. |
Multiple sclerosis [8A40]
|
[15] |
Deflazacort |
DMV0RNS
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Deflazacort. |
Muscular dystrophy [8C70]
|
[12] |
Bexarotene |
DMOBIKY
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Bexarotene. |
Mycosis fungoides [2B01]
|
[12] |
Romidepsin |
DMT5GNL
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Romidepsin. |
Mycosis fungoides [2B01]
|
[12] |
Decitabine |
DMQL8XJ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Decitabine. |
Myelodysplastic syndrome [2A37]
|
[12] |
Azacitidine |
DMTA5OE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Azacitidine. |
Myelodysplastic syndrome [2A37]
|
[12] |
Nilotinib |
DM7HXWT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Ruxolitinib |
DM7Q98D
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ruxolitinib. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Dasatinib |
DMJV2EK
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Hydroxyurea |
DMOQVU9
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Hydroxyurea. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Busulfan |
DMXYJ9C
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Busulfan. |
Myeloproliferative neoplasm [2A20]
|
[12] |
Inebilizumab |
DMI0RHA
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Inebilizumab. |
Nervous system paraneoplastic/autoimmune disorder [8E4A]
|
[12] |
Atezolizumab |
DMMF8U0
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Atezolizumab. |
Non-small cell lung cancer [2C25]
|
[12] |
Olaparib |
DM8QB1D
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Olaparib. |
Ovarian cancer [2C73]
|
[12] |
Carboplatin |
DMG281S
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Carboplatin. |
Ovarian cancer [2C73]
|
[12] |
Altretamine |
DMKLAYG
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Altretamine. |
Ovarian cancer [2C73]
|
[12] |
MK-4827 |
DMLYGH4
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and MK-4827. |
Ovarian cancer [2C73]
|
[12] |
Topotecan |
DMP6G8T
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Topotecan. |
Ovarian cancer [2C73]
|
[12] |
Buprenorphine |
DMPRI8G
|
Moderate |
Altered metabolism of Infliximab due to Buprenorphine alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[15] |
Hydrocodone |
DMQ2JO5
|
Moderate |
Altered metabolism of Infliximab due to Hydrocodone alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[15] |
Oxycodone |
DMXLKHV
|
Moderate |
Altered metabolism of Infliximab due to Oxycodone alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[15] |
Streptozocin |
DMOF7AT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Streptozocin. |
Pancreatic cancer [2C10]
|
[12] |
Levamisole |
DM5EN79
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Levamisole. |
Parasitic infection [1D0Y-1G2Z]
|
[12] |
Pemetrexed |
DMMX2E6
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Pemetrexed. |
Pleural mesothelioma [2C26]
|
[12] |
Prednisone |
DM2HG4X
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[12] |
Betamethasone |
DMAHJEF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Betamethasone. |
Postoperative inflammation [1A00-CA43]
|
[12] |
Hydrocortisone |
DMGEMB7
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[12] |
Everolimus |
DM8X2EH
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Everolimus. |
Renal cell carcinoma [2C90]
|
[12] |
Temsirolimus |
DMS104F
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[12] |
Upadacitinib |
DM32B5U
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Upadacitinib. |
Rheumatoid arthritis [FA20]
|
[15] |
Canakinumab |
DM8HLO5
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[14] |
Rilonacept |
DMGLUQS
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[14] |
Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Golimumab. |
Rheumatoid arthritis [FA20]
|
[12] |
Dexamethasone |
DMMWZET
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Dexamethasone. |
Rheumatoid arthritis [FA20]
|
[12] |
Abatacept |
DMSA8RU
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Abatacept. |
Rheumatoid arthritis [FA20]
|
[28] |
Fentanyl |
DM8WAHT
|
Moderate |
Altered metabolism of Infliximab due to Fentanyl alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[15] |
Sufentanil |
DMU7YEL
|
Moderate |
Altered metabolism of Infliximab due to Sufentanil alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[15] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Infliximab when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[29] |
Mogamulizumab |
DMISH0Z
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mogamulizumab. |
Sezary syndrome [2B02]
|
[12] |
Floxuridine |
DM04LR2
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Floxuridine. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Dactinomycin |
DM2YGNW
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Dactinomycin. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Methylprednisolone |
DM4BDON
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Cyclophosphamide |
DM4O2Z7
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Cyclophosphamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Vinblastine |
DM5TVS3
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Vinblastine. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
PDX-101 |
DM6OC53
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and PDX-101. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Ifosfamide |
DMCT3I8
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ifosfamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Docetaxel |
DMDI269
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Trabectedin |
DMG3Y89
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Mitoxantrone |
DMM39BF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mitoxantrone. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
LEE011 |
DMMX75K
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Etoposide |
DMNH3PG
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Etoposide. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Epirubicin |
DMPDW6T
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Prednisolone |
DMQ8FR2
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Cisplatin |
DMRHGI9
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Cisplatin. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Gemcitabine |
DMSE3I7
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Gemcitabine. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Norethindrone |
DMTY169
|
Moderate |
Altered metabolism of Infliximab due to Norethindrone alters the formation of CYP450 enzymes. |
Solid tumour/cancer [2A00-2F9Z]
|
[17] |
Fluorouracil |
DMUM7HZ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Fluorouracil. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Taxol |
DMUOT9V
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Taxol. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Doxorubicin |
DMVP5YE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Vinorelbine |
DMVXFYE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Vinorelbine. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Infliximab and Naltrexone. |
Substance abuse [6C40]
|
[30] |
Warfarin |
DMJYCVW
|
Moderate |
Altered metabolism of Infliximab due to Warfarin alters the formation of CYP450 enzymes. |
Supraventricular tachyarrhythmia [BC81]
|
[15] |
Pomalidomide |
DMTGBAX
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Pomalidomide. |
Systemic sclerosis [4A42]
|
[12] |
Plicamycin |
DM7C8YV
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Plicamycin. |
Testicular cancer [2C80]
|
[12] |
Apixaban |
DM89JLN
|
Moderate |
Altered metabolism of Infliximab due to Apixaban alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[15] |
Trimetrexate |
DMDEA85
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Trimetrexate. |
Toxoplasmosis [1F57]
|
[12] |
Muromonab |
DM8ANCF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Muromonab. |
Transplant rejection [NE84]
|
[12] |
Sirolimus |
DMGW1ID
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Sirolimus. |
Transplant rejection [NE84]
|
[12] |
Azathioprine |
DMMZSXQ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Azathioprine. |
Transplant rejection [NE84]
|
[12] |
Mycophenolate mofetil |
DMPQAGE
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Mycophenolate mofetil. |
Transplant rejection [NE84]
|
[12] |
Basiliximab |
DMWNRZT
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Basiliximab. |
Transplant rejection [NE84]
|
[12] |
Belatacept |
DMXLYQF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Belatacept. |
Transplant rejection [NE84]
|
[12] |
Tacrolimus |
DMZ7XNQ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Tacrolimus. |
Transplant rejection [NE84]
|
[12] |
Durvalumab |
DM4PVDY
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Durvalumab. |
Ureteral cancer [2C92]
|
[12] |
Triamcinolone |
DM98IXF
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Triamcinolone. |
Vasomotor/allergic rhinitis [CA08]
|
[12] |
Disopyramide |
DM5SYZP
|
Moderate |
Altered metabolism of Infliximab due to Disopyramide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Mexiletine |
DMCTE9R
|
Moderate |
Altered metabolism of Infliximab due to Mexiletine alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Procainamide |
DMNMXR8
|
Moderate |
Altered metabolism of Infliximab due to Procainamide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Propafenone |
DMPIBJK
|
Moderate |
Altered metabolism of Infliximab due to Propafenone alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Flecainide |
DMSQDLE
|
Moderate |
Altered metabolism of Infliximab due to Flecainide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Amiodarone |
DMUTEX3
|
Moderate |
Altered metabolism of Infliximab due to Amiodarone alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Ganciclovir |
DM1MBYQ
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[12] |
Trifluridine |
DMG2YBD
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Trifluridine. |
Virus infection [1A24-1D9Z]
|
[12] |
Valganciclovir |
DMS2IUH
|
Major |
Additive immunosuppressive effects by the combination of Infliximab and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[12] |
----------- |
|
|
|
|
|